Normalization of Pulmonary Hypertension by the Use of Left Ventricular Assist Device in Patients with End-stage Heart Failure: A聽Possible Contribution to Donor Pool Expansion in Lung Transplantation

详细信息    查看全文

• 作者：Hirokazu Akashi¹ ; ² ; ^{akashi@juntendo.ac.jp" class="auth_mail} ; Tomoko S. Kato³ ; ⁴ ; Kazuhiko Hashimura⁵ ; Masafumi Kitakaze⁴ ; Khurram Shahzad³ ; Maryjane Farr³ ; Mancini Donna³ ; Hiroo Takayama¹ ; Yoshifumi Naka¹ ; Taira Yamamoto² ; Atsushi Amano²
• 关键词：left ventricular assist device ; lung transplantation ; pulmonary vascular resistance
• 刊名：International Journal of Gerontology
• 出版年：March, 2014
• 年：2014
• 卷：8
• 期：1
• 页码：42-44
• 全文大小：407 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Heart transplantation alone has been recognized to be contraindicated when pulmonary hypertension (PH) and elevated pulmonary vascular resistance (PVR) are irreversible, irrespective of any medical intervention by the use of inotropic agents or pulmonary vasodilators, because such patients are at an increased risk of post-transplantation right ventricular failure and mortality. Therefore, end-stage heart failure patients with concomitant fixed PH and irreversibly high PVR are considered to be heart-lung transplant candidates. Recently, left ventricular assist device (LVAD) therapy has been reported to normalize PVR through persistent unloading of the left ventricle, even in patients with medically refractory PH. Therefore, LVAD therapy could make such patients suitable for 鈥渉eart-only鈥?transplants, which contributes to appropriate donor lung allocation for lung-only candidates. We review the literature regarding LVAD use for secondary PH and present a case with end-stage heart failure that could avoid a heart-lung transplant owing to LVAD therapy.